Login / Signup

Combination with portosystemic shunt occlusion and antiviral therapy improves prognosis of decompensated cirrhosis.

Hideyuki TamaiHiroki MinamiguchiYoshiyuki IdaNaoki ShingakiTokuro MurokiShuya MaeshimaRyo ShimizuJunpei OkamuraTakao KoyamaTaisei NakaoTetsuo Sonomura
Published in: JGH open : an open access journal of gastroenterology and hepatology (2020)
SVN in patients with viral hepatitis appears prerequisite to maintaining recovered liver function by shunt occlusion and to improving prognosis. Combination therapy with shunt occlusion and antiviral treatment should be considered as a first-line treatment for decompensated cirrhotic patients with viral hepatitis and large portosystemic shunt growth.
Keyphrases
  • combination therapy
  • pulmonary artery
  • heart failure
  • sars cov
  • coronary artery
  • pulmonary hypertension
  • pulmonary arterial hypertension
  • liver failure
  • stem cells
  • ejection fraction
  • bone marrow